Alcidion Buys Kyra Patient Flow Tools From Telstra Health Adding 31 New Hospital Customers
Alcidion strengthens patient flow leadership with Kyra acquisition from Telstra Health
Alcidion Group Limited (ASX: ALC) has signed an Asset Sale Agreement (ASA) to acquire the Kyra Patient Flow Manager, Kyra Queue Manager and Kyra IQ (collectively, the “Kyra flow products”) from Telstra Health. The Alcidion Kyra flow products acquisition is structured as a $3.0M upfront payment plus an earn-out of up to $1.0M, with the Kyra business forecast to generate $3.7M in revenue and $1.1M in underlying EBITDA for FY26, implying an upfront EBITDA multiple of 2.7x. The transaction is expected to be earnings accretive from completion, anticipated by the end of June 2026.
Investors can join a live webcast and Q&A hosted by Group Managing Director and CEO Kate Quirke on Monday, 18 May 2026 at 11:30am AEST via Zoom registration.
When big ASX news breaks, our subscribers know first
What are the Kyra flow products and why do they matter?
Three complementary solutions for hospital patient flow
Managing patient flow in a hospital is one of the most operationally complex challenges in modern healthcare. From the moment a patient arrives at emergency through to discharge, clinicians and administrators must coordinate bed availability, triage, referral management, and data access across multiple systems. With an ageing population and rising hospital admission rates placing sustained pressure on health services, validated digital tools that reduce this burden are in growing demand.
The Kyra flow products address these challenges through three distinct but complementary solutions:
| Product | Function |
|---|---|
| Kyra Patient Flow Manager | Provides clinicians and administrative teams real-time oversight of a patient’s hospital journey from admission through to discharge, enabling proactive bed management and resourcing decisions |
| Kyra Queue Manager | A comprehensive outpatient solution covering patient check-ins, wayfinding, referral management, triage and billing capability |
| Kyra IQ | A data warehouse that consolidates health data from multiple disparate systems into real-time operational dashboards and administrative reports |
Kyra IQ functions as a data consolidation layer, complementing the two operational products by surfacing aggregated insights that support decision-making across inpatient and outpatient settings.
Why patient flow is a high-value niche in digital health
Patient flow software becomes deeply embedded in clinical workflows over time, creating high switching costs for hospital customers. Once a health service has configured its bed management, triage, and reporting processes around a particular platform, replacement carries substantial operational risk.
The Kyra customer base reflects this dynamic clearly. The top 10 customers hold an average relationship of approximately 10 years, and more than 90% of Kyra revenue is generated from recurring support and maintenance contracts. For investors, this revenue profile signals both quality and predictability.
31 net-new customers and a Queensland breakthrough
Expanding the customer map across five states
Of Kyra’s approximately 33 long-standing customers, only 2 are existing Alcidion customers. That means 31 represent net-new relationships, materially expanding Alcidion’s footprint across Australian public and private health services.
The Queensland opportunity is particularly notable. Kyra Patient Flow Manager and Queue Manager are used by the majority of Queensland Hospital and Health Services, a market where Alcidion previously had limited scale. The company’s existing 5-year contract with Gold Coast Health (itself a Kyra customer) demonstrates an established Queensland presence, and this acquisition positions Alcidion to build substantively on that foundation.
Beyond Queensland, the acquisition adds new customers in Victoria across both public and private sectors, building on Alcidion’s existing patient flow relationships with Hume, Peninsula Health, Western Health and Alfred. Further additions in WA and Tasmania round out a customer map that now spans five of six Australian states.
Financial snapshot
The transaction presents a straightforward financial profile. The $3.0M upfront payment is funded entirely from existing cash reserves. As of 31 March 2026, Alcidion held $15.1M in cash with no debt, meaning the acquisition requires no new capital. The earn-out of up to $1.0M is conditional on recurring revenue metrics being met over the 12 months following completion.
| Metric | Detail |
|---|---|
| FY26F Revenue (Kyra) | $3.7M |
| Underlying EBITDA (FY26F) | $1.1M |
| Upfront Purchase Price | $3.0M |
| Earn-out (conditional) | Up to $1.0M, tied to recurring revenue metrics assessed over 12 months post-completion |
| Upfront EBITDA Multiple | 2.7x |
| Funding Source | Existing cash reserves ($15.1M cash, no debt as at 31 March 2026) |
CEO Kate Quirke
“This acquisition is highly complementary to our core business and further consolidates our market position in the Australian patient flow market. There is strong strategic and financial alignment as we continue to build a scaled, recurring revenue-driven health technology company.”
The next major ASX story will hit our subscribers first
What happens next for Alcidion investors
Integration and the path to synergies
The transaction is expected to be earnings accretive from completion on a pre-synergy basis. This is a meaningful distinction: the financial case holds before any cross-selling has occurred. The 31 net-new Kyra customers represent a potential pipeline for Alcidion’s flagship Miya Precision platform, though that upside is not yet reflected in the acquisition’s financial metrics.
Alcidion has described itself as one of few industry players with the infrastructure, credibility, and expertise required to serve enterprise government and private health customers at this scale. The company has also indicated it expects to maintain an ongoing relationship with Telstra Health, given the complementary nature of their respective product suites.
Key dates and milestones to watch
- 18 May 2026, 11:30am AEST: Investor webcast and Q&A hosted by CEO Kate Quirke
- End of June 2026: Anticipated completion of the acquisition, subject to closing conditions
- 12 months post-completion: Earn-out assessment window, tied to recurring revenue thresholds
Telstra Health Managing Director, Elizabeth Koff AM
“Alcidion brings strong capability, deep industry expertise and a proven track record supporting hospitals. We are confident they are well placed to continue to evolve these products for customers.”
With $3.7M in forecast recurring revenue, a 2.7x EBITDA entry multiple, and 31 net-new customer relationships now in scope for Miya Precision cross-selling, the acquisition adds tangible scale to Alcidion’s recurring revenue base. For investors watching the company’s long-term strategy, this is a disciplined, cash-funded bolt-on in a structurally growing segment of digital health, delivered at an attractive price.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.